Unknown

Dataset Information

0

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.

ABSTRACT:

SUBMITTER: Rule S 

PROVIDER: S-EPMC6518912 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
| S-EPMC4513941 | biostudies-literature
Unknown Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
| S-EPMC7686907 | biostudies-literature
Unknown Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
| S-EPMC6853811 | biostudies-literature
Unknown Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
| S-EPMC5198949 | biostudies-literature
Unknown Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
| S-EPMC3811905 | biostudies-literature
Unknown Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
| S-EPMC5877869 | biostudies-literature
Unknown Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
| S-EPMC8556975 | biostudies-literature
Unknown Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
| S-EPMC6776792 | biostudies-literature
Unknown Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).
| S-EPMC8446834 | biostudies-literature
Unknown Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
| S-EPMC8270663 | biostudies-literature